What is the initial step to order for a primary aldosteronism screen?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Initial Screening for Primary Aldosteronism

Order a simultaneous plasma aldosterone concentration and plasma renin activity (or direct renin concentration) to calculate the aldosterone-to-renin ratio (ARR), which is the recommended initial screening test. 1, 2

Who Should Be Screened

Screen patients with any of the following high-risk features: 1, 2

  • Resistant hypertension (BP uncontrolled on 3 medications including a diuretic) - present in up to 20% of these patients 2, 3
  • Spontaneous or substantial diuretic-induced hypokalemia 1
  • Incidentally discovered adrenal mass on imaging 1, 2
  • Family history of early-onset hypertension or stroke at young age (<40 years) 1, 2
  • Severe hypertension (BP >180/110 mmHg) 2
  • Well-controlled hypertension with first-degree relative with primary aldosteronism, atrial fibrillation, or obstructive sleep apnea 3

Critical pitfall: Do not rely on hypokalemia as a screening trigger—it is absent in 50% of primary aldosteronism cases. 2, 3

Patient Preparation Before Testing

Potassium Repletion

  • Ensure serum potassium is normal before testing, as hypokalemia suppresses aldosterone production and causes false-negative results 2

Medication Management

When clinically feasible, adjust interfering medications: 1, 2

  • Stop these medications (cause false-positives by suppressing renin): beta-blockers, centrally acting antihypertensives (clonidine), and diuretics 2
  • Use these alternatives (minimal ARR interference): long-acting calcium channel blockers and alpha-receptor antagonists 2
  • If medications cannot be stopped, interpret results in the context of the specific drugs the patient is taking 2
  • Withdraw mineralocorticoid receptor antagonists (spironolactone, eplerenone) at least 4 weeks before testing 2

Salt Intake

  • Patients should have unrestricted salt intake before testing 2

Blood Collection Technique

Follow this specific protocol for accurate results: 2

  • Collect blood in the morning 2
  • Patient should be out of bed for 2 hours prior to collection 2
  • Patient should be seated for 5-15 minutes immediately before blood draw 2
  • Draw blood with patient in seated position 2

Interpreting the ARR

Positive Screening Test Criteria

A positive screen requires BOTH of the following: 1, 2

  • ARR ≥30 (when aldosterone is in ng/dL and plasma renin activity is in ng/mL/h) 1, 2
  • Plasma aldosterone concentration ≥10-15 ng/dL 2

The ARR has excellent sensitivity and specificity (>90%) when using these cutoffs. 2

Additional Interpretation Notes

  • The specificity improves if a minimum plasma renin activity of 0.5 ng/mL/h is used in calculations 2
  • Different assay methods (chemiluminescent immunoassay vs radioimmunoassay) are both reliable, with chemiluminescent showing 90% sensitivity and 99% specificity 4

Next Steps After Positive Screening

Confirmatory Testing Required

A positive ARR always requires confirmatory testing to demonstrate autonomous aldosterone secretion that cannot be suppressed. 2, 3 Options include: 2, 3

  • Oral sodium loading test with 24-hour urine aldosterone measurement
  • Intravenous saline suppression test (2L normal saline over 4 hours; failure to suppress plasma aldosterone below 5 ng/dL confirms diagnosis) 2
  • Captopril challenge test 3
  • Fludrocortisone suppression test 3

Referral

Refer all patients with positive screening tests to a hypertension specialist or endocrinologist for confirmatory testing, subtype determination, and treatment planning. 1, 2

Common Diagnostic Pitfalls to Avoid

  • Do not proceed to surgery based on CT findings alone—adrenal venous sampling is mandatory to distinguish unilateral from bilateral disease (except in patients <40 years with single adenoma on imaging) 2
  • Do not assume normal potassium excludes the diagnosis—hypokalemia is present in only 50% of cases 2, 3
  • Do not perform testing while patient is on spironolactone or eplerenone—these must be withdrawn at least 4 weeks prior 2
  • Only 2-4% of eligible high-risk patients are actually screened, representing significant underdiagnosis 2, 3

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Screening for Primary Aldosteronism

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Primary Aldosteronism.

American family physician, 2023

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.